Manufacturing Glycosylated Erythropoietin Without 𝛼1,3-Fucosylation Using The EntoEngine™

Glycosylation plays a critical role in determining the safety, efficacy, and biological performance of therapeutic proteins. Using erythropoietin (EPO) as a model protein, this case study examines how a whole-insect expression approach can generate glycosylated recombinant proteins while addressing challenges associated with conventional production platforms. It highlights the importance of N-glycan structure, site occupancy, and glycosylation consistency, all of which influence bioactivity, stability, and immunogenicity.

Experimental analyses demonstrate successful glycosylation across all three EPO N-glycosylation sites, consistent glycan profiles between production batches, and strong biological activity in cell-based assays. Notably, the resulting glycan structures lacked α1,3-linked fucose, a modification often associated with non-human glycosylation patterns and potential immunogenicity concerns. The findings provide insight into how alternative expression systems can be leveraged to produce functional glycoproteins with reproducible quality attributes and controlled post-translational modifications.

For organizations developing complex biologics, these results offer a practical look at the relationship between expression host selection, glycosylation outcomes, and therapeutic protein performance.